Response to neoadjuvant chemotherapy leads to better survival outcomes in upper tract urothelial carcinoma
BJU International · 2025
DOI: 10.1111/bju.16655 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift BJU International, 2025. Verfasst von Alice Yu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Moffitt Cancer Center, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Carcinoma, Transitional Cell, Ureteral Neoplasms, Kidney Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: the Paracelsus Medical University Research and Innovation Fund, Eleanor and Scott Petty Fund for Research on UTUC, Monteleone Family Foundation for Research in Kidney and Bladder Cancer.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
To evaluate the benefit of neoadjuvant chemotherapy (NAC) for patients with high‐risk upper tract urothelial carcinoma (UTUC) using a large, well‐curated multi‐institutional database. Patients and Methods This study was a multi‐institutional retrospective analysis conducted by the UTUC Collaborative Network (UCAN), combining data from 2276 patients with UTUC who underwent radical nephroureterectomy at seven high‐volume tertiary care centres in the United States. The UCAN data were analysed to evaluate the impact of response to NAC on survival outcomes in patients with UTUC.
Results
A total of 378 patients in the UCAN database underwent NAC. On final surgical pathology, 101 patients (26.8%) had ≤ypT1N0 disease and were defined as NAC treatment responders. Patients who responded to NAC had significantly longer overall survival (OS) and progression‐free survival (PFS) compared to non‐responders. At 5 years post‐surgery, 81.5% of responders were alive compared to 59.8% of non‐responders. The median OS and PFS times among non‐responders were 7.0 years (95% confidence interval [CI] 5.6–9.7) and 6.0 years (95% CI 4.6–9.3) respectively, while the median OS and PFS were not reached among responders. Limitations of this study include its retrospective design, heterogeneity in chemotherapy regimens, and the absence of clearly defined patient selection criteria for treatment.
Conclusion
These data suggest that NAC can play a pivotal role in the treatment of well‐selected UTUC patients who respond positively. Non‐responders had clearly inferior outcomes. More work is needed to find predictors of response which can improve patient selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Moffitt Cancer Center, Tampa, Florida, USA.
- University of Kentucky, Lexington, Kentucky, USA.
- Mayo Clinic, Rochester, Minnesota, USA.
- Penn State Health, Hershey, Pennsylvania, USA.
- Johns Hopkins University, Baltimore, Maryland, USA.
- University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
ORCID-Profile: Alice Yu, Austin Martin, Maximilian Pallauf, Vitaly Margulis, Surena F Matin
Förderung
- the Paracelsus Medical University Research and Innovation Fund
- Eleanor and Scott Petty Fund for Research on UTUC
- Monteleone Family Foundation for Research in Kidney and Bladder Cancer
Zitieren
APA
Yu, A., Hensley, P. J., Huelster, H. L., Martin, A., Potrezke, A., Pham, J., Raman, J. D., Pallauf, M., Singla, N., Katims, A., Coleman, J., Margulis, V., Matin, S. F., & Spiess, P. E. (2025). Response to neoadjuvant chemotherapy leads to better survival outcomes in upper tract urothelial carcinoma. BJU International. https://doi.org/10.1111/bju.16655
Vancouver
Yu A, Hensley PJ, Huelster HL, Martin A, Potrezke A, Pham J, et al. Response to neoadjuvant chemotherapy leads to better survival outcomes in upper tract urothelial carcinoma. BJU International. 2025. doi:10.1111/bju.16655
BibTeX
@article{Yu2025,
author = {Yu, Alice and Hensley, Patrick J and Huelster, Heather L and Martin, Austin and Potrezke, Aaron and Pham, Jonathan and Raman, Jay D and Pallauf, Maximilian and Singla, Nirmish and Katims, Andrew and Coleman, Jonathan and Margulis, Vitaly and Matin, Surena F and Spiess, Philippe E},
title = {Response to neoadjuvant chemotherapy leads to better survival outcomes in upper tract urothelial carcinoma},
journal = {BJU International},
year = {2025},
doi = {10.1111/bju.16655}
}
EUVIMED